CD40LG and lung adenocarcinoma: Consequently, a number of clinical trials have been conducted to test the so-called GM.CD40L bystander cell line, which is a K562 MHC-negative GM-CSF-secreting CD40L-expressing cell line, in the formulation of tumor cell-based vaccines in lung adenocarcinoma patients [185,186,187].